The world is facing a microbe-based pandemic, and that means an onslaught of diseases is sweeping the planet.

While antibiotics, antiviral medications and other modern therapies can fight off many infections, they are not a cure-all.

And if they fail, there’s no guarantee that they’ll be effective.

That’s why a team of researchers led by Dr. Hervé Tournier, a professor of microbiology and immunology at McGill University, has created a new drug, microbe vaccine, that can treat the ills of the world’s ills.

The vaccine has a unique mechanism that allows it to target and destroy bacteria that cause infections.

The drug is made from a bacterium that has evolved to become resistant to antibiotics.

The team has shown that it works in mice and in people.

The research was published this week in Science. 

The drug has a mechanism that enables it to attack and destroy bacterial infections The drug was developed by Drs.

Tourniers team and Prof. Rolfe W. Jenssen, director of the University of North Carolina Center for Infectious Disease Research, the largest laboratory in the United States for the study of bacterial infections.

“Microbial infections are caused by a lot of bacteria that are very hard to get rid of.

The problem is that it’s hard to isolate and test these bacteria to see what they’re actually doing.

We don’t know enough about them, so we can’t know what they really are,” said Tourners team leader and McGill professor of immunology and infectious disease.

“This drug, if used correctly, could be a new way to identify these bacteria, and to treat them.

It could be an effective treatment for a lot more infections than antibiotics.”

The drug targets bacteria that can cause pneumonia and tuberculosis, two of the major causes of infections in the world.

These are the same bacteria that caused outbreaks of the coronavirus in the U.S. and Europe.

The study found that the drug works in humans and mice and that it has the ability to eliminate or destroy a large number of bacteria.

That means it can effectively target and kill the bacteria that spread the diseases.

“The key is that we don’t need a drug to treat infection,” said Dr. Tommaso Caligiuri, a postdoctoral researcher in the lab of Tournieri and his colleagues.

“We don’t have to go to a hospital and have an injection and see if it works.

We can test it in our laboratory, in our lab in our clinic.

So we can test and see, if it does work, we can then test it out in our clinical setting, and then see if we can do something about it.”

The team also found that a single dose of the drug can kill about two bacteria per milliliter of blood, which is the standard dosage for an antibiotic.

The new drug is not effective against a broad range of bacteria, but it is effective at eliminating certain strains of bacteria like the Candida species, which causes serious infections in people and animals.

Candida is the most common cause of bloodstream infections.

In humans, it causes an inflammation of the small blood vessels that carry oxygen from the lungs to the brain.

This can lead to neurological complications and even death.

The researchers believe that the Candides have evolved to evade antibiotic treatments and are resistant to all antibiotics, but they have not yet been identified.

To fight Candides, TournIER used a method known as selective targeting.

“You want to target specific strains, you want to get the most resistant strains,” he said.

“It’s a very elegant method that we’re not even sure how it works.”

The group’s previous drug, called Lymphocyte Translates, was only effective in mice, which means that it did not kill all Candides.

However, in humans, the Candids are so widespread that it is hard to find a specific strain that does not exist in humans.

The scientists are now working on a vaccine for Candides that could be used in humans as soon as the end of this year.

The first human trial of the new drug was published in the Journal of Antimicrobial Chemotherapy, which describes the results of the research.

“I think the challenge for the next few years is to try to develop a vaccine that is as effective as the Lymphocytes vaccine,” Tourner said.

Microbiologist Dr. M. Filippi, director at the National Institute of Allergy and Infectious Diseases, also welcomed the new work.

“Using a bacteriophage to eradicate Candides is a wonderful strategy that is not only feasible but could be very effective,” he told Newsweek.

“There are still many unknowns, including how the Candidases behave in the body, what happens in the liver when they infect, what